![](/img/cover-not-exists.png)
238PDA randomized, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast cancer
Pegram, M., Tan-Chiu, E., Freyman, A., Vana, A., Hilton, F., Zacharchuk, C., Ewesuedo, R.Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx365.001a
Date:
September, 2017
File:
PDF, 79 KB
english, 2017